R&D Supercharging clinical development with RWE – with Recursion... Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.
Digital “Data is our currency” – with Ginkgo Datapoints’ John Andros... Successful use of AI is becoming a key differentiator for pharma companies.
Patients How pharma is tackling new direct-to-patient programmes At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Patients Direct-to-patient is more than just telehealth – with EVERSA... Hear from EVERSANA's Faruk Abdullah in this video interview as he explains why direct-to-patient strategies go beyond telehealth.
Patients New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.
Market Access Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
